The Influence of KIR and HLA Genotype on the Response to Rituximab Immunotherapy in Patients With Follicular Lymphoma
- To test the influence of killer immunoglobulin-like receptor (KIR) and human lymphocyte
antigen (HLA) genotype on response to anti-CD20 antibody lymphoma immunotherapy.
OUTLINE: DNA samples are analyzed for killer immunoglobulin-like receptor (KIR) and human
lymphocyte antigen (HLA) genotyping with sequence-specific primers (SSP) by real-time PCR.
KIR and HLA typing are analyzed according to KIR-HLA matched vs mismatched, KIR B haplotype
content, and the number of inhibitory KIR-HLA pairs. Results are then correlated to each
patient's overall response and duration of response to rituximab.
KIR-HLA genotype predictive of antibody-dependent cell-mediated cytotoxicity (ADCC)-based cancer immunotherapy
Erik Ranheim, MD, PhD
University of Wisconsin, Madison